Quantum BioPharma reports strong Q2 with increased assets, no debt

NEW YORK - Quantum BioPharma Ltd. (NASDAQ:QNTM), currently valued at $89.7 million in market capitalization, reported increased assets and elimination of all debt liabilities in its second quarter financial results ending June 30, 2025, according to a company press release. InvestingPro analysis indicates the company maintains a "Fair" overall financial health score.

The biopharmaceutical company’s current assets rose to $10.3 million as of June 30, compared to $9.9 million at the end of the previous quarter. Total assets increased to $15.3 million from $14.9 million in the same period.

Quantum BioPharma converted all outstanding debentures into equity, eliminating debt liabilities associated with debentures issued in late 2024 and early 2025. The company reported having sufficient cash to maintain basic operations beyond March 2027.

The company’s stock price nearly tripled from $7.71 at the close of Q1 to $20.25 at the end of Q2, and has since reached $26.14, delivering an impressive 610% return year-to-date. Its cryptocurrency reserves appreciated by over $500,000, according to the statement. With a beta of 1.62, the stock shows higher volatility than the broader market. InvestingPro analysis suggests the stock is currently trading above its Fair Value.

Operating expenses increased to $4.9 million for the quarter, up from $3.4 million in Q1, primarily due to share-based payments and legal expenses. External research and development fees decreased to $0.6 million from $1.7 million in the previous quarter.

Quantum BioPharma continues to advance clinical trials for Lucid-21-302, its multiple sclerosis drug candidate. Phase 1 oral toxicity studies showed no toxicity or side effects, and the company has begun a joint study with Massachusetts General Hospital using PET scan imaging to monitor demyelination in MS patients.

The company’s licensee for unbuzzd, a supplement that accelerates alcohol metabolism, has commercialized the product in the United States and launched a Regulation D offering to raise up to $5 million to support growth and a potential initial public offering.

As of June 30, Quantum BioPharma had 3,815,835 Class B Subordinate Voting Shares outstanding, with 66% held through depository nominees and 34% by registered holders. The stock trades at a price-to-book ratio of 15.65x, reflecting investor optimism about future growth potential. Discover more valuable insights about QNTM with InvestingPro, which offers 8 additional exclusive tips and comprehensive financial metrics.

In other recent news, Quantum BioPharma Ltd. reported the completion of a Phase 1 clinical study for its multiple sclerosis treatment candidate, Lucid-MS. The study, conducted by its subsidiary Huge Biopharma Australia, showed no safety or tolerability concerns in healthy participants. Additionally, the company completed a non-brokered private placement of class A multiple voting shares, raising $600, with existing shareholders expected to subscribe to the entire offering. In collaboration with Massachusetts General Hospital, Quantum BioPharma also announced the first scanning of a multiple sclerosis patient in a study to validate a novel PET imaging technique. This study uses the PET tracer [18F]3F4AP developed by Dr. Pedro Brugarolas. Moreover, Quantum BioPharma plans to declare a special dividend tied to ongoing legal action, offering Contingent Value Rights to Class B Subordinate Voting Shareholders. The litigation seeks damages exceeding $700 million related to alleged stock price manipulation by CIBC World Markets, RBC Dominion Securities, and others.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.